Cells and Procedure Well Tolerated; Gains in Sensory Function Confirmed NEWARK, Calif., Sept. 3, 2012 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) today announced that interim six-month data from the first patient cohort in the Company’s Phase I/II clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) for chronic spinal cord injury [...] Read more »